Elite Diagnostic Limited (JMSE:ELITE)
Jamaica
· Delayed Price · Currency is JMD 1.500
-0.060 (-3.85%)
At close: Dec 5, 2025
Elite Diagnostic Income Statement
Financials in millions JMD. Fiscal year is July - June.
Millions JMD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Revenue | 868.26 | 853.82 | 821.28 | 755.33 | 624.22 | 506.91 | Upgrade
|
| Revenue Growth (YoY) | 4.87% | 3.96% | 8.73% | 21.00% | 23.14% | 15.26% | Upgrade
|
| Cost of Revenue | 261.01 | 269.69 | 278.13 | 277.27 | 223.58 | 200.5 | Upgrade
|
| Gross Profit | 607.24 | 584.14 | 543.16 | 478.06 | 400.64 | 306.4 | Upgrade
|
| Selling, General & Admin | 340.23 | 342.65 | 311.39 | 276.9 | 210.66 | 174.77 | Upgrade
|
| Operating Expenses | 512.7 | 512.76 | 446.61 | 413.35 | 318.19 | 276.83 | Upgrade
|
| Operating Income | 94.54 | 71.38 | 96.54 | 64.71 | 82.45 | 29.58 | Upgrade
|
| Interest Expense | -28.82 | -28.24 | -48.64 | -32.67 | -27.33 | -21.02 | Upgrade
|
| Interest & Investment Income | 0.13 | 0.13 | 0.09 | 0.1 | 0.01 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.3 | 2.62 | -3.32 | -4.56 | -6.47 | -6.72 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.29 | -10.9 | -14.15 | -14.2 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 58.87 | 34.99 | 30.53 | 13.39 | 48.66 | 1.93 | Upgrade
|
| Asset Writedown | 1.93 | 1.93 | -1.18 | - | - | - | Upgrade
|
| Pretax Income | 60.81 | 36.92 | 29.35 | 13.39 | 48.66 | 1.93 | Upgrade
|
| Income Tax Expense | 5.24 | 4.9 | 3.19 | 0.04 | - | - | Upgrade
|
| Net Income | 55.56 | 32.02 | 26.16 | 13.35 | 48.66 | 1.93 | Upgrade
|
| Net Income to Common | 55.56 | 32.02 | 26.16 | 13.35 | 48.66 | 1.93 | Upgrade
|
| Net Income Growth | 175.14% | 22.44% | 95.90% | -72.56% | 2422.31% | -77.44% | Upgrade
|
| Shares Outstanding (Basic) | 353 | 353 | 353 | 353 | 353 | 353 | Upgrade
|
| Shares Outstanding (Diluted) | 353 | 353 | 353 | 353 | 353 | 353 | Upgrade
|
| EPS (Basic) | 0.16 | 0.09 | 0.07 | 0.04 | 0.14 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.09 | 0.07 | 0.04 | 0.14 | 0.01 | Upgrade
|
| EPS Growth | 175.14% | 22.44% | 95.91% | -72.56% | 2422.72% | -77.45% | Upgrade
|
| Free Cash Flow | 163.09 | 167.95 | 92.29 | -25.87 | -127.87 | 38.8 | Upgrade
|
| Free Cash Flow Per Share | 0.46 | 0.47 | 0.26 | -0.07 | -0.36 | 0.11 | Upgrade
|
| Dividend Per Share | 0.010 | 0.010 | - | - | 0.020 | 0.090 | Upgrade
|
| Dividend Growth | - | - | - | - | -77.78% | - | Upgrade
|
| Gross Margin | 69.94% | 68.41% | 66.14% | 63.29% | 64.18% | 60.45% | Upgrade
|
| Operating Margin | 10.89% | 8.36% | 11.76% | 8.57% | 13.21% | 5.83% | Upgrade
|
| Profit Margin | 6.40% | 3.75% | 3.19% | 1.77% | 7.80% | 0.38% | Upgrade
|
| Free Cash Flow Margin | 18.78% | 19.67% | 11.24% | -3.43% | -20.48% | 7.65% | Upgrade
|
| EBITDA | 232 | 206.47 | 199.83 | 173.05 | 177.25 | 116.11 | Upgrade
|
| EBITDA Margin | 26.72% | 24.18% | 24.33% | 22.91% | 28.40% | 22.91% | Upgrade
|
| D&A For EBITDA | 137.46 | 135.1 | 103.29 | 108.33 | 94.8 | 86.53 | Upgrade
|
| EBIT | 94.54 | 71.38 | 96.54 | 64.71 | 82.45 | 29.58 | Upgrade
|
| EBIT Margin | 10.89% | 8.36% | 11.76% | 8.57% | 13.21% | 5.83% | Upgrade
|
| Effective Tax Rate | 8.62% | 13.27% | 10.88% | 0.26% | - | - | Upgrade
|
| Advertising Expenses | - | 3.42 | 5.23 | 9.61 | 5.9 | 4.06 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.